Mendus Management

Management Kriterienprüfungen 1/4

Mendus' CEO ist Erik Manting , ernannt in Mar 2021, hat eine Amtszeit von 3.25 Jahren. besitzt direkt 0.46% der Aktien des Unternehmens, im Wert von SEK2.11M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 2.9 Jahre.

Wichtige Informationen

Erik Manting

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.3yrs
Eigentum des Geschäftsführers	0.5%
Durchschnittliche Amtszeit des Managements	3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.9yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Erik Manting (53 yo)

3.3yrs

Amtszeit

Dr. Erik Manting, Ph D., has been the Chief Executive Officer at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Exec...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Erik Manting	Chief Executive Officer	3.3yrs	keine Daten	0.46% SEK 2.1m
Alex Karlsson-Parra	Co-Founder & Chief Scientific Officer	16.4yrs	kr1.42m	keine Daten
Lotta Ferm	Chief Financial Officer	3.3yrs	keine Daten	0.20% SEK 884.0k
Leopold Bertea	Chief Technology Officer	2.1yrs	keine Daten	keine Daten
Jeroen Rovers	Chief Medical Officer	no data	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: IMMUDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ada Kruisbeek	Chair of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Sven Andreasson	Independent chairman	4.2yrs	kr325.00k	keine Daten
Lewis Lanier	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Hans Preusting	Independent Director	3.1yrs	kr330.00k	keine Daten
Helen Tuvesson	Independent Director	4.2yrs	kr355.00k	keine Daten
Tanja de Gruijl	Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Dharminder Chahal	Independent Director	3.4yrs	kr355.00k	0.44% SEK 1.9m
Inge Svane	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Sjoerd van Burg	Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Ted Fjallman	Independent Director	less than a year	kr285.00k	keine Daten

2.9yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: IMMUDie Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Mendus Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Chief Executive Officer recently bought kr120k worth of stock

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB (publ), Annual General Meeting, May 17, 2024

Recent updates

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

Chief Executive Officer recently bought kr120k worth of stock

We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate

Mendus AB (Publ) Announces Clinical Pipeline Update

Consensus revenue estimates increase by 172%

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Consensus revenue estimates decrease by 63%

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates increase by 172%

Mendus AB (publ), Annual General Meeting, May 17, 2024

New major risk - Share price stability

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Mendus (STO:IMMU) Is Making Moderate Use Of Debt

Price target decreased by 23% to kr5.00

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Is Mendus (STO:IMMU) Using Debt Sensibly?

Price target decreased to kr5.30

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Is Mendus (STO:IMMU) Using Debt Sensibly?

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Chief Financial Officer recently bought kr216k worth of stock

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr97k worth of stock

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Is Immunicum (STO:IMMU) Using Too Much Debt?

Chief Executive Officer recently bought kr252k worth of stock

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought kr2.4m worth of stock

Interim Chairman of the Board recently bought kr183k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Executive Officer has left the company

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

New 90-day low: kr6.84

Independent Chairman Michael S. Oredsson has left the company